University of Ioannina
Επίδραση της θεραπείας με στατίνη σε μεταβολικές παραμέτρους σε ασθενείς με πρωτοπαθή δυσλιπιδαιμία
Abstract
dc:descriptionObjective: In this study we assessed the effect of rosuvastatin 10-20 mg/day on the serumlipid profile and metabolic variables considered as vascular risk predictors in patients withdyslipidemia.Material and methods: A hundred and fifty patients with dyslipidemia were randomized by2:1 to rosuvastatin 10 (RSV10 group) or 20 mg/day (RSV20 group). At baseline as well as 12weeks post-treatment the following parameters were determined: 1] the serum lipid profile, 2]the cholesterol concentration of different size and density lipoprotein [low density lipoproteins(LDL) and high density lipoproteins (HDL)] particles, 3] the mean LDL size, 4] the totalplasma enzyme activity of lipoprotein-associated phospholipase A2 (LpPLA2) or thatassociated with lipoprotein particles, 5] the enzyme activity of paraoxonase-1 (PON1), and, 6]the plasma visfatin levels.Results: One hundred and twenty four patients (80 in the RSV10 and 44 in the RSV20 group)completed the study protocol. Rosuvastatin effectively reduced total cholesterol (TC),triglycerides (TG), low density lipoprotein cholesterol (LDL-C) and apolipoprotein (apo)B,while raised high density lipoprotein cholesterol (HDL-C) and apoA1 levels. These changeswere dose-dependent. Also, rosuvastatin was associated with a dose-dependent effect on thecholesterol concentration of lipoprotein particles with different size and density. Namely,rosuvastatin 10 mg/day significantly reduced the cholesterol of all LDL particles in concert,thus, not affecting the mean LDL size. In contrast, rosuvastatin 20 mg/day predominantlydecreased the cholesterol mass of the atherogenic small-dense LDL (sdLDL), compared withthe large and buoyant LDL (lbLDL). In this context, a small though significant increase in themean LDL size was noted in the RSV20 group. The same was relevant among patients with baseline TG levels ≥ 120 and ≥ 150 mg/dl in the RSV10 and RSV20 group respectively.Furthermore, a dose-dependent effect of rosuvastatin on the cholesterol mass of HDLsubfractions was noted. Namely, rosuvastatin 10 mg/day significantly increased the cholesterolconcentration of the large and intermediate HDL, while 20 mg/day of only the large HDL. Thecholesterol mass of small HDL remained unchanged.Plasma LpPLA2 as well as the enzyme activity associated with apoB-rich lipoproteins wassignificantly reduced in a dose-dependent manner. In contrast, no significant effect ofrosuvastatin on LpPLA2 activity associated with HDL was noted. Likewise, rosuvastatininduced no relevant change in PON1 activity towards paraoxon and phenylacetate.Rosuvastatin 10 mg/day significantly reduced plasma visfatin levels independently of its lipidmodifying effects.Conclusion: Rosuvastatin not only beneficially changes the serum lipid profile, but also exertsvarious actions that could contribute to a better vascular risk profile of patients withdyslipidemia.
Degree
thesis:*- Grantor dc:publisher
- University of Ioannina
- Year dc:date
- 2014
Author and committee
dc:creator, dc:contributor.*- Authors dc:creator
-
- Kostapanos, Michalis
- Κωσταπάνος, Μιχαήλ
Subjects
dc:subject × 22- Στατίνη
- Ροσουβαστατίνη
- Δυσλιπιδαιμία
- Παράγοντες κινδύνου
- Καρδιαγγειακή νόσος
- Φωσφολιπάση Α2, Συνδεδεμένη με τις λιποπρωτεΐνες
- Υποκλάσματα λιποπρωτεϊνών
- Παραοξονάση
- Βισφατίνη
- Statin
- Rosuvastatin
- Dyslipidemias
- Risk factors
- Cardiovascular disease
- Lipoprotein associated phospholipase A2
- Lipoprotein subclasses
- Paraoxonase
- Visfatin
- Ιατρική και Επιστήμες Υγείας
- Κλινική Ιατρική
- Medical and Health Sciences
- Clinical Medicine
Rights
- Language dc:language
- gre
Identifiers
dc:identifier.*- Identifier
- 10.12681/eadd/30080